Finoriq research workspace
Acrivon Therapeutics, Inc. (ACRV) Historical Metrics
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops. Review ACRV valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
- Company
- Acrivon Therapeutics, Inc. (ACRV)
- Ticker
- ACRV
- Market Cap
- $74M
- Latest Price
- $1.73
- Industry
- Biotech & Pharma
Acrivon Therapeutics, Inc. (ACRV) Current Valuation Metrics
Static valuation preview for Acrivon Therapeutics, Inc. (ACRV). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -89.1% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -74.6% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.91x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.